Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Mayne Pharma Group (MAYNF) vs. Competitors

24 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
MAYNFMayne Pharma Group$2.16$177.09M10.35-34.55%Moderate BuyUnlock the MAYNF analyst price target with TipRanks PremiumMAYNFUnlock the MAYNF top-analyst price target with TipRanks Premium
AU:SPLStarpharma Holdings LimitedAUD 0.42AUD 202.82M-24.562.69%―Unlock the AU:SPL analyst price target with TipRanks PremiumMAYNF vs AU:SPLUnlock the AU:SPL top-analyst price target with TipRanks Premium
AU:VLSVita Life Sciences LimitedAUD 2.64AUD 141.68M13.2010.00%―Unlock the AU:VLS analyst price target with TipRanks PremiumMAYNF vs AU:VLSUnlock the AU:VLS top-analyst price target with TipRanks Premium
AU:MVPMedical Developments International LimitedAUD 0.42AUD 46.75M74.11-25.23%Moderate BuyUnlock the AU:MVP analyst price target with TipRanks PremiumMAYNF vs AU:MVPUnlock the AU:MVP top-analyst price target with TipRanks Premium
AU:BOTBotanix Pharmaceuticals LimitedAUD 0.01AUD 22.10M-0.25-92.31%Moderate BuyUnlock the AU:BOT analyst price target with TipRanks PremiumMAYNF vs AU:BOTUnlock the AU:BOT top-analyst price target with TipRanks Premium
AU:RCERecce Pharmaceuticals Ltd.AUD 0.37AUD 113.19M-7.14-14.94%―Unlock the AU:RCE analyst price target with TipRanks PremiumMAYNF vs AU:RCEUnlock the AU:RCE top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
MAYNFMayne Pharma Group2.16-1.02-32.18%
AU:SPLStarpharma Holdings Limited0.420.012.69%
AU:VLSVita Life Sciences Limited2.640.3716.35%
AU:MVPMedical Developments International Limited0.41-0.10-18.63%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.12-92.00%
AU:RCERecce Pharmaceuticals Ltd.0.37-0.07-14.94%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts